✦ LIBER ✦

O-91 First line treatment with gemcitabine (G) and vinorelbine (V) versus cisplatin (C) gemcitabine and vinorelbine (CGV) in advanced non small cell lung cancer (NSCLC). Preliminary results of a randomised study of the GON (Grupo Oncológico del Norte de Espan˜a)

✍ Scribed by Esteban, Emilio; Fra, Joaquin; Vietez, Jose María; Palacio, Isabel; De Sande, Jose Luis; Fernández, Jose Luis; Mun˜iz, Isabel; Villanueva, Noemi; Estrada, Enrique; Lacave, Angel

Book ID: 118571482
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 331 KB
Volume: 41
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(03)91749-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-537 Cisplatin plus gemcitabine with or

P-537 Cisplatin plus gemcitabine with or without vinorelbine as neoadjuvant therapy for radically-treatable stage II non small cell lung cancer (NSCLC). Preliminary results of a randomised study of the GON (grupo Oncológico del Norte de Espan˜a)

✍ De Sande, Jose Luis; Esteban, Emilio; Fernández, Yolanda; Fra, Joaquin; Palacio, 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 176 KB

O-113 Cisplatin plus gemcitabine with or

O-113 Cisplatin plus gemcitabine with or without vinorelbine asneo-adjuvant therapy for radically treatable stage III Non small cell lung cancer (NSCLC). Preliminary results of a randomised study of the GON (Grupo Oncológico del Norte de España)

✍ Esteban, E.; Fernández, Y.; Vieitez, J.; Villanueva, N.; De Sande, J.; Fra, J.; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 142 KB

PD-147 A phase I study of a second gener

PD-147 A phase I study of a second generation antisenseoligonucleotide to clusterin (OGX-011) in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC): Preliminary results

✍ Laskin, J.; Chi, K.; Melosky, B.; Sill, K.; Hao, D.; Canil, C.; Gleave, M.; Murr 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 129 KB

P-976 EGFR mutation analysis in a random

P-976 EGFR mutation analysis in a randomized phase II study of cetuximab (Erbitux™) in combination with cisplatin (C) and vinorelbine (V) vs CV alone in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) patients (pts)

✍ Szczesna, A.; Taron, M.; Robinet, G.; Ramlau, R.; Pfeifer, W.; Kolb, R.; Consten 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 117 KB

Preliminary results of a randomized stud

Preliminary results of a randomized study on first and second line chemotherapy strategy in stage IV non-small cell lung cancer (NSCLC), assessing docetaxel (D) and cisplatin (C) until progressive disease (PD) then vinorelbine (V) versus V-C until PD then D

✍ Douillard, J; Gervais, R; Lacroix, H; Le Groumellec, A; Spaeth, D; D'arlhac, M; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 227 KB